Stay updated on Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.

Latest updates to the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page
- Check6 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3. No study content or user-facing functionality were changed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded site Revision: v3.4.2. Removed the government funding/operating status notice from the page.SummaryDifference0.5%

- Check41 days agoChange DetectedAdded a government funding notice and a site revision notice (Revision: v3.4.1); removed the previous revision (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check48 days agoChange DetectedShow glossary toggle added and minor UI label changes (e.g., capitalization in 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'). The footer revision now shows v3.4.0.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 is shown, replacing v3.3.3. No user-facing content or study details appear to be affected.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section with Oregon as a study site, updating core participation details. Removed the old Oregon Locations label and the HHS Vulnerability Disclosure link; revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.